Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety rollover study of daratumumab in multiple myeloma
ISRCTN99312021Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Oct 2024; status: recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN99312021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN99312021.